SG10201402977WA - Pyrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases - Google Patents
Pyrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinasesInfo
- Publication number
- SG10201402977WA SG10201402977WA SG10201402977WA SG10201402977WA SG10201402977WA SG 10201402977W A SG10201402977W A SG 10201402977WA SG 10201402977W A SG10201402977W A SG 10201402977WA SG 10201402977W A SG10201402977W A SG 10201402977WA SG 10201402977W A SG10201402977W A SG 10201402977WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrolo
- inhibition
- pyridine derivatives
- raf kinases
- raf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15939609P | 2009-03-11 | 2009-03-11 | |
| US15939009P | 2009-03-11 | 2009-03-11 | |
| US15939209P | 2009-03-11 | 2009-03-11 | |
| US15940609P | 2009-03-11 | 2009-03-11 | |
| US15940009P | 2009-03-11 | 2009-03-11 | |
| US15939509P | 2009-03-11 | 2009-03-11 | |
| US15940209P | 2009-03-11 | 2009-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201402977WA true SG10201402977WA (en) | 2014-09-26 |
Family
ID=42199540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011063914A SG174257A1 (en) | 2009-03-11 | 2010-03-10 | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
| SG10201402977WA SG10201402977WA (en) | 2009-03-11 | 2010-03-10 | Pyrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011063914A SG174257A1 (en) | 2009-03-11 | 2010-03-10 | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8901301B2 (en) |
| EP (1) | EP2406259A1 (en) |
| JP (1) | JP2012520307A (en) |
| KR (1) | KR101663339B1 (en) |
| CN (1) | CN102421776A (en) |
| AR (1) | AR075812A1 (en) |
| AU (1) | AU2010224245B2 (en) |
| BR (1) | BRPI1011515A2 (en) |
| CA (1) | CA2755045A1 (en) |
| CO (1) | CO6620074A2 (en) |
| CR (1) | CR20110476A (en) |
| EC (1) | ECSP11011313A (en) |
| MA (1) | MA33181B1 (en) |
| MX (1) | MX2011009489A (en) |
| MY (1) | MY161861A (en) |
| NI (1) | NI201100168A (en) |
| NO (1) | NO20111241A1 (en) |
| PE (1) | PE20120184A1 (en) |
| RU (1) | RU2011141123A (en) |
| SG (2) | SG174257A1 (en) |
| TW (1) | TW201036973A (en) |
| WO (1) | WO2010104945A1 (en) |
| ZA (1) | ZA201106599B (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP2012509342A (en) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | Substituted pyrrolo [2,3-B] -pyridine and -pyrazine |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| PE20121327A1 (en) | 2009-11-06 | 2012-10-18 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES, AND INDICATIONS THEREOF |
| CA2781287C (en) | 2009-11-18 | 2018-07-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX2012007429A (en) * | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
| TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| JP2013526570A (en) | 2010-05-14 | 2013-06-24 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Fused bicyclic kinase inhibitor |
| AR081039A1 (en) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | QUINASA FUSIONED BICYCLE INHIBITORS |
| US8771687B2 (en) | 2010-12-02 | 2014-07-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for treating a tumor using an antibody that specifically binds GRP94 |
| PL2672967T3 (en) * | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012149547A1 (en) * | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| EP2709622A4 (en) | 2011-05-17 | 2015-03-04 | Plexxikon Inc | Kinase modulation and indications therefor |
| US9988687B2 (en) * | 2011-09-20 | 2018-06-05 | The George Washington Univeristy | Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants |
| EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| MX367055B (en) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof. |
| TWI601725B (en) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
| AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014081760A1 (en) | 2012-11-20 | 2014-05-30 | Duke University | Methods of treating hemoglobinopathies |
| AR094263A1 (en) | 2012-12-21 | 2015-07-22 | Plexxikon Inc | PROTEINQUINAS SELECTIVE MODULATING COMPOUNDS |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| JP2016519684A (en) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects |
| BR112015028845A2 (en) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compounds for kinase modulation and indications thereof |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RS60731B1 (en) | 2015-05-06 | 2020-09-30 | Plexxikon Inc | Solid forms of a compound modulating kinases |
| KR102637844B1 (en) | 2015-05-06 | 2024-02-19 | 다이이치 산쿄 인코포레이티드 | Synthesis of 1H-pyrrolo[2,3B]pyridine derivatives that regulate kinases |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
| CA3007462C (en) | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2017232610B2 (en) | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
| JP7193460B2 (en) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Compounds and methods for CDK8 modulation and indications thereof |
| CA3049926A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| WO2019023198A1 (en) | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| CN111194318B (en) | 2017-10-13 | 2023-06-09 | Opna生物公司 | Solid forms of compounds for modulating kinases |
| AU2018354423A1 (en) | 2017-10-27 | 2020-05-14 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| SG11202007143UA (en) | 2018-01-31 | 2020-08-28 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2020016243A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| MX2021012278A (en) | 2019-04-09 | 2021-11-12 | Plexxikon Inc | Condensed azines for ep300 or cbp modulation and indications therefor. |
| AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
| AU2021327375A1 (en) | 2020-08-21 | 2023-03-16 | Opna Bio SA | Combinational drug anticancer therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516417B (en) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | Cyclodextrin-based polymers for therapeutics delivery |
| AU2006261993B2 (en) * | 2005-06-22 | 2011-11-17 | Plexxikon, Inc. | Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors |
| PE20081581A1 (en) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
-
2010
- 2010-03-10 EP EP10708681A patent/EP2406259A1/en not_active Withdrawn
- 2010-03-10 CA CA2755045A patent/CA2755045A1/en not_active Abandoned
- 2010-03-10 WO PCT/US2010/026816 patent/WO2010104945A1/en active Application Filing
- 2010-03-10 PE PE2011001620A patent/PE20120184A1/en not_active Application Discontinuation
- 2010-03-10 CN CN2010800206771A patent/CN102421776A/en active Pending
- 2010-03-10 SG SG2011063914A patent/SG174257A1/en unknown
- 2010-03-10 MA MA34228A patent/MA33181B1/en unknown
- 2010-03-10 TW TW099106990A patent/TW201036973A/en unknown
- 2010-03-10 AU AU2010224245A patent/AU2010224245B2/en active Active
- 2010-03-10 MX MX2011009489A patent/MX2011009489A/en not_active Application Discontinuation
- 2010-03-10 SG SG10201402977WA patent/SG10201402977WA/en unknown
- 2010-03-10 KR KR1020117023712A patent/KR101663339B1/en active IP Right Grant
- 2010-03-10 MY MYPI2011004233A patent/MY161861A/en unknown
- 2010-03-10 AR ARP100100731A patent/AR075812A1/en unknown
- 2010-03-10 US US12/721,496 patent/US8901301B2/en active Active
- 2010-03-10 RU RU2011141123/04A patent/RU2011141123A/en unknown
- 2010-03-10 BR BRPI1011515A patent/BRPI1011515A2/en not_active Application Discontinuation
- 2010-03-10 JP JP2011554147A patent/JP2012520307A/en not_active Withdrawn
-
2011
- 2011-08-09 EC EC2011011313A patent/ECSP11011313A/en unknown
- 2011-09-06 CR CR20110476A patent/CR20110476A/en unknown
- 2011-09-08 ZA ZA2011/06599A patent/ZA201106599B/en unknown
- 2011-09-09 NI NI201100168A patent/NI201100168A/en unknown
- 2011-09-12 CO CO11117856A patent/CO6620074A2/en not_active Application Discontinuation
- 2011-09-13 NO NO20111241A patent/NO20111241A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201106599B (en) | 2014-02-26 |
| PE20120184A1 (en) | 2012-03-28 |
| TW201036973A (en) | 2010-10-16 |
| MY161861A (en) | 2017-05-15 |
| US20100286178A1 (en) | 2010-11-11 |
| AU2010224245B2 (en) | 2016-07-21 |
| CA2755045A1 (en) | 2010-09-16 |
| CN102421776A (en) | 2012-04-18 |
| NO20111241A1 (en) | 2011-09-28 |
| AR075812A1 (en) | 2011-04-27 |
| US8901301B2 (en) | 2014-12-02 |
| BRPI1011515A2 (en) | 2016-03-29 |
| NI201100168A (en) | 2012-01-11 |
| RU2011141123A (en) | 2013-04-20 |
| KR101663339B1 (en) | 2016-10-06 |
| WO2010104945A1 (en) | 2010-09-16 |
| EP2406259A1 (en) | 2012-01-18 |
| ECSP11011313A (en) | 2011-10-31 |
| JP2012520307A (en) | 2012-09-06 |
| KR20110125670A (en) | 2011-11-21 |
| MA33181B1 (en) | 2012-04-02 |
| CO6620074A2 (en) | 2013-02-15 |
| MX2011009489A (en) | 2011-10-11 |
| AU2010224245A1 (en) | 2011-09-29 |
| SG174257A1 (en) | 2011-10-28 |
| CR20110476A (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201402977WA (en) | Pyrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases | |
| AP2939A (en) | Thieno [2,3-B] pyridine derivatives as viral replication inhibitors | |
| IL235745A (en) | 2-aminopyridine derivatives | |
| ZA201108124B (en) | Pyrrolo [2,3-b] pyridines which inhibit raf protein kinase | |
| ZA201201125B (en) | Pyridin-4-yl derivatives | |
| IL217798A0 (en) | Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors | |
| EP2205611A4 (en) | Processes for the preparation of prasugrel, and its salts and polymorphs | |
| IL215725A0 (en) | 3-([1,2,3]-triazol-4-yl)pyrrolo[2,3-b]pyridine derivatives | |
| IL214426A0 (en) | [1,2,4] triazollo [1,5-a] pyridines as kinase inhibitors | |
| ZA201107350B (en) | Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives | |
| IL218617A (en) | Pyridinylimidazolone derivatives for the inhibition of pi3 kinases | |
| HK1200447A1 (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors 1h-[2,3-b] | |
| ZA201100437B (en) | 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors | |
| IL232717B (en) | 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives | |
| ME01914B (en) | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[ 4, 3-c]isoquinoline derivatives | |
| IL210074A (en) | Process for the preparation of derivatives of pyrido[2,3-d]pyrimidine-7-yl-phenyl | |
| HK1201441A1 (en) | Process for the preparation of substituted pyrimidine derivatives | |
| IL205082A0 (en) | Process for the preparation of tetranorlabdane derivatives | |
| IL219138A0 (en) | Process for the preparation of 4-sulfinyl-pyrazole derivatives | |
| SI2155679T1 (en) | Method for the production of 4-formylaminopiperidine derivatives | |
| EP2490693A4 (en) | PYRAZOLO [3,4-b]PYRIDIN-4-ONE KINASE INHIBITORS | |
| EP2595994A4 (en) | Process for preparing pyrano - [2,3-c]pyridine derivatives | |
| IL214957A0 (en) | Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases | |
| PL390846A1 (en) | Derivatives of 5,11-dimethyl-5H-indole [2,3-b] quinoline | |
| IL219623A0 (en) | [1,5]-diazocin derivatives |